News & Events
September 16, 2021
TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community Oncology Practices
Key Partnership Will Connect Patients with Precision Oncology Clinical Trials and Novel Therapies, Accelerating Access to Promising Treatments Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will enhance access to tailored oncology treatments and novel clinical studies for patients receiving care in community oncology practices. The partnership will enable TD2 to offer Deep Lens’ proprietary...
November 24, 2020
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)
The Companies Plan to Focus On Voltron’s VaxCelerate Vaccine Platform’s Effectiveness and Utility in...
October 29, 2020
TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology Practices
Partnership Will Accelerate the Awareness and Adoption of Precision Oncology in Private Practices and...
September 28, 2020
Applied Clinical Trials: Small Biopharma and CROs: Seeking Stronger Synergies
Many emerging biopharmaceutical companies hire contract research organizations (CROs) because of limited...